Developing strategies for detection of gene doping

Journal of Gene Medicine

Volumn 10, Issue 1, 2008, Pages 3-20

  Baoutina, Anna ^a   Alexander, Ian E ^b   Rasko, John E J ^c   Emslie, Kerry R ^a  

^a NATIONAL MEASUREMENT INSTITUTE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Athletic performance; Detection; Gene doping; Profiling; Sport; Vectors

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; ERYTHROPOIETIN; GENOMIC DNA; HEMOGLOBIN; MOLECULAR MARKER; PARVOVIRUS VECTOR; PLASMID DNA; RECOMBINANT ERYTHROPOIETIN; SMALL INTERFERING RNA;

ATHLETE; BIOLOGICAL MONITORING; BLOOD ANALYSIS; BODY DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORRELATION ANALYSIS; DOPING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FECES ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; GENE TECHNOLOGY; GENE TRANSFER; GENE VECTOR; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOPHILIA A; HUMAN; IN VIVO STUDY; INNATE IMMUNITY; ISOELECTRIC FOCUSING; LIMB ISCHEMIA; METABOLOMICS; MICROARRAY ANALYSIS; MUSCULAR DYSTROPHY; NON INVASIVE PROCEDURE; NONHUMAN; NOSE MUCUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUALITATIVE ANALYSIS; RETICULOCYTE COUNT; REVIEW; SALIVA ANALYSIS; SAMPLING; SENSITIVITY ANALYSIS; SOUTHERN BLOTTING; STANDARDIZATION; TRANSCRIPTOMICS; TRANSGENE; URINALYSIS; VIRAL GENE THERAPY;

DOPING IN SPORTS; GENE EXPRESSION PROFILING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNITY; TRANSGENES;

EID: 38349127842     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1114     Document Type: Review

References (149)

1. WADA. Available: http://www.wada-ama.org/rtecontent,/document/ 2006_LIST.pdf. Accessed: April 2007.
2. Schneider AJ, Friedmann T. Gene doping in sports: the science and ethics of genetically modified athletes. Adv Genet 2006; 51: 1-110.
3. Baoutina A, Alexander IE, Rasko JE, et al. Potential use of gene transfer in athletic performance enhancement. Mol Ther 2007; 15: 1751-1766.
4. Baum C. What are the consequences of the fourth case? Mol Ther 2007; 15: 1401-14022.
5. Retracing events. Nat Biotechnol 2007; 25: 949.
6. IOC. Available: http://www.olyTnpic.org/uk/news/media_centre/ press_release_uk.asp?id=609. Accessed April 2007.
7. Friedmann T, Koss JO. Gene transfer and athletics- an impending problem. Mol Ther 2001; 3: 819-820.
8. Haisma HJ, de Hon O. Gene doping. Int J Sports Med 2006; 27: 257-266.
9. Miah A. Rethinking enhancement in sport. Ann N Y Acad Sci 2006; 1093: 301-320.
10. Azzazy HM, Mansour MM, Christenson RH. Doping in the recombinant era: strategies and counterstrategies. Clin Biochem 2005; 38: 959-965.
11. Lasne F, Martin L, de Ceaurriz J, et al. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther 2004; 10: 409-410.
12. Stieger K, Le Meur G, Lasne F, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006; 13: 967-975.
13. Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-138.
14. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195-200.
15. Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda) 2005; 20: 232-238.
16. Yew NS. Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev 2005; 57: 769-780.
17. Papadakis ED, Nicklin SA, Baker AH, et al. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 2004; 4: 89-113.
18. Dash PR, Read ML, Barrett LB, et al. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther 1999; 6: 643-650.
19. Oh YK, Kim JP, Yoon H, et al. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther 2001; 8: 1587-1592.
20. Zhang JS, Liu F, Conwell CC, et al. Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther 2006; 13: 429-437.
21. Oh YK, Kim JP, Hwang TS, et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 2001; 19: 4519-4525.
22. Koshkina NV, Agoulnik TY, Melton SL, et al. Biodistribution and pharmacokinetics of aerosol and intravenously adrninistered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 2003; 8: 249-254.
23. Parker SE, Borellini F, Wenk ML, et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10: 741-758.
24. Quezada A, Larson J, French M, et al. Biodistribution and safety studies of hDeI-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 2004; 56: 177-185.
25. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007; 13: 372-377.
26. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007.
27. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-462.
28. Thomas SM, Zeng Q, Dyer KF, et al. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther 2003; 10: 518-528.
29. Romero NB, Braun S, Benveniste O, et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 2004; 15: 1065-1076.
30. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002; 35: 930-936.
31. O'Malley BW, Jr., Li D, McQuone SJ, et al. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 2005; 115: 391-404.
32. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 2004; 78: 6381-6388.
33. Grossman Z, Mendelson E, Brok-Simoni F, et al. Detection of adeno-associated virus type 2 in human peripheral blood cells. J Gen Virol 1992; 73: 961-966.
34. Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001; 4: 559-566.
35. Hernandez YJ, Wang J, Kearns WG, et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73: 8549-8558.
36. Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 2005; 16: 1276-1286.
37. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
38. Arruda VR, Stedman HH, Nichols TC, et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
39. Nathwani AC, Davidoff AM, Hanawa H, et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002; 100: 1662-1669.
40. Gao G, Lu Y, Calcedo R, et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
41. Ponnazhagan S, Mukherjee P, Yoder MC, et al. Adeno-associated virus 2-mediated gene transfer in vivo: organtropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
42. Manno CS, Arruda VR, Pierce GF, et al. Successful transduction of liver in hemophilia byAAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
43. Flomenberg P, Gutierrez E, Piaskowski V, et al. Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. J Med Virol 1997; 51: 182-188.
44. Wildner O, Morris JC. Subcutaneous Administration of a Replication-Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, Persistence, Shedding, and Pathogenicity. Hum Gene Ther 2002; 13: 101-112.
45. Plog MS, Guyre CA, Roberts BL, et al. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Hum Gene Ther 2006; 17: 705-716.
46. Smith TA, Idamakanti N, Marshall-Neff J, et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595-1604.
47. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther2002; 5: 695-704.
48. Lozier JN, Csako G, Mondoro TH, et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 2002; 13: 113-124.
49. Printz MA, Gonzalez AM, Cunningham M, et al. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther 2000; 11: 191-204.
50. Ni S, Bernt K, Gaggar A, et al. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005; 16: 664-677.
51. Hiltunen MO, Turunen MP, Turtmen AM, et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. Faseb J 2000; 14: 2230-2236.
52. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976.
53. Griscelli F, Opolon P, Saulnier P, et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 2003; 10: 386-395.
54. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000; 18: 609-622.
55. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
56. Palmer DH, Mautner V, Mirza D, et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004; 22: 1546-1552.
57. Dummer R, Bergh J, Karlsson Y, et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000; 7: 1069-1076.
58. Cavazzana-Calvo M. Lagresle C, Hacein-Bey-Abina S, et al. Gene therapy for severe combined immunodeficiency. Annu Rev Med 2005; 56: 585-602.
59. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
60. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
61. Powell JS, Ragni MV, White GC, 2nd, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102: 2038-2045.
62. Seppen J, Barry SC, Harder B, et al. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 2001; 98: 594-596.
63. Schellingerhout D, Bogdanov A, Jr., Marecos E, et al. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543-1549.
64. Schellingerhout D, Rainov NG, Breakefield XO, et al. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther 2000; 7: 1648-1655.
65. Todo T, Feigenbaum F, Rabkin SD, et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2000; 2: 588-595.
66. Wolfe D, Niranjan A. Trichel A, et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther 2004; 11: 1675-1684.
67. Varghese S, Newsome JT, Rabkin SD, et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther 2001; 12: 999-1010.
68. WADA. Available: http://www.wada-ama.org/en/ dynamic.ch2?pageCategory.id=347. Accessed April 2007.
69. Rivera VM, Gao GP, Grant RL, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424-1430.
70. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15: 1157-1166.
71. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11(Suppl 1): S10-17.
72. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
73. Smith JS, Tian J, Lozier JN, et al. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther 2004; 9: 932-941.
74. Varnavski AN, Calcedo R, Bove M, et al. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Ther 2005; 12: 427-436.
75. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583.
76. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 2003; 10: 935-940.
77. Zhang YC, Powers M, Wasserfall C, et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Ther 2004; 11: 233-240.
78. Wakimoto H, Johnson PR, Knipe DM, et al. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003; 10: 983-990.
79. Hukkanen V, Broberg E, Sahni A, et al. Cytokines in experimental herpes simplex virus infection. Int Rev Immunol 2002; 21: 355-371.
80. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16: 96-113.
81. Broberg EK, Hukkanen V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr Gene Ther 2005; 5: 523-530.
82. Brockman MA, Knipe DM. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 2002; 76: 3678-3687.
83. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-3709.
84. Gilkeson GS, Conover J, Halpern M, et al. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J Immunol 1998; 161: 3890-3895.
85. Tan Y, Liu F, Li Z, et al. Sequential injection of cationic liposome and plasmid DNA effectively transfects; the lung with minimal inflammatory toxicity. Mol Ther 2001; 3: 673-682.
86. Riviere C, Danos O, Douar AM. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 2006; 13: 1300-1308.
87. Chirmule N, Xiao W, Truneh A, et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-2425.
88. Harvey BG, Hackett NR, El-Sawy T, et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999; 73: 6729-6742.
89. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133.
90. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 1995; 122: 889-898.
91. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176: 1129-1134.
92. McCormack MP, Gonda TJ. Expression of activated mutants of the human interleukin-3/interleukin-5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. Blood 1997; 90: 1471-1481.
93. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther 2001; 3: 516-525.
94. Tait DL, Obermiller PS, Hatmaker AR, et al. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999; 5: 1708-1714.
95. Abordo-Adesida E, Follenzi A, Barcia C, et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther 2005; 16: 741-751.
96. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 2003; 48: 300-312.
97. Lv S, Zhang J, Wu J, et al. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol Lett 2005; 99: 217-227.
98. Tran TT, Reich CF, 3rd, Alam M, et al. Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. Clin Immunol 2003; 109: 278-287.
99. MacColl G, Bunn C, Goldspink G, et al. Intramuscular plasmid DNA injection can accelerate autoimmune responses. Gene Ther 2001; 8: 1354-1356.
100. Conry RM, White SA, Fultz PN, et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 1998; 4: 2903-2912.
101. Favre D, Blouin V, Provost N, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76: 11605-11611.
102. Latta-Mahieu M, Rolland M, Caillet C, et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620.
103. Lena AM, Giannetti P, Sporeno E, et al. Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector. J Gene Med 2005; 7: 1086-1096.
104. Richard P, Pollard H, Lanctin C, et al. Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation. J Gene Med 2005; 7: 80-86.
105. Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004; 103: 3303-3304.
106. Gao G, Lebherz C, Weiner DJ, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103: 3300-3302.
107. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
108. Nakayama M, Both GW, Banizs B, et al. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 2006; 350: 103-115.
109. Keriel A, Rene C, Galer C, et al. Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J Virol 2006; 80: 1487-1496.
110. De BP, Heguy A, Hackett NR, et al. High levels of persistent expression of alphal-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006; 13: 67-76.
111. Hodges BL, Taylor KM, Joseph MF, et al. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.
112. Judge AD, Bola G, Lee AC, et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13: 494-505.
113. Murphy D. Gene expression studies using microarrays: principles, problems, and prospects. Adv Physiol Educ 2002; 26: 256-270.
114. Elvidge G. Microarray expression technology: from start to finish. Pharmacogenomics 2006; 7: 123-134.
115. Kuo WP, Liu F, Trimarchi J, et al. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat Biotechnol 2006; 24: 832-840.
116. Mahoney DJ, Parise G, Melov S, et al. Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. Faseb J 2005; 19: 1498-1500.
117. Zieker D, Fehrenbach E, Dietzsch J, et al. cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. Physiol Genomics 2005; 23: 287-294.
118. Labrie F, Luu-The V, Calvo E, et al. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol 2005; 184: 427-433.
119. Reiter M, Walf VM, Christians A, et al. Modification of mRNA expression after treatment with anabolic agents and the usefulness for gene expression-biomarkers. Anal Chim Acta 2007; 586: 73-81.
120. Yates JR III. Mass spectral analysis in proteomics. Annu Rev Biophys Biomol Struct 2004; 33: 297-316.
121. Pasa-Tolic L, Masselon C, Barry RC, et al. Proteomic analyses using an accurate mass and time tag strategy. Biotechniques 2004; 37: 621-624, 626-633, 636 passim.
122. Resing KA, Ahn NG. Proteomics strategies for protein identification. FEBS Lett 2005; 579: 885-889.
123. Larsen MR, Trelle MB, Thinghohn TE, et al. Analysis of posttranslational modifications of proteins by tandem mass spectrometry. Biotechniques 2006; 40: 790-798.
124. Lu P, Vogel C, Wang R, et al. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 2007; 25: 117-124.
125. Mallick P, Schirle M, Chen SS, et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 2007; 25: 125-131.
126. Rinner O, Mueller LN, Hubalek M, et al. An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat Biotechnol 2007; 25: 345-352.
127. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005; 563: 23-60.
128. Walker SJ, Xu A. Biomarker discovery using molecular profiling approaches. Int Rev Neurobiol 2004; 61: 1-30.
129. Chung L, Clifford D, Buckley M, et al. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab 2006; 91: 671-677.
130. Dall R, Longobardi S, Ehrnborg C, et al. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab 2000; 85: 4193-4200.
131. Abellan R, Ventura R, Pichini S, et al. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse. Int J Sports Med 2007; 28: 9-15.
132. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606-625.
133. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8: 1439-1444.
134. Sabatine MS, Liu E, Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112: 3868-3875.
135. Petibois C, Cazorla G, Poortmans JR, et al. Biochemical aspects of overtraining in endurance sports: a review. Sports Med 2002; 32: 867-878.
136. Petibois C, Deleris G, Cazorla G. Perspectives in the utilisation of Fourier-transform infrared spectroscopy of serum in sports medicine: health monitoring of athletes and prevention of doping. Sports Med 2000; 29: 387-396.
137. Bijlsma S, Bobeldijk I, Verheij ER, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 2006; 78: 567-574.
138. Boernsen KO, Gatzek S, Imbert G. Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. Anal Chem 2005; 77: 7255-7264.
139. Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007; 35: D521-526.
140. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: a feasibility study. Haematologica 2003; 88: 570-581.
141. Eleno TG, Kiehr B, Baunsgaard D, et al. Combination of'omics' data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers. Biomarkers 2004; 9: 116-138.
142. Rantalainen M, Cloarec O, Beckonert O, et al. Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J Proteome Res 2006; 5: 2642-2655.
143. Niemeyer CM, Adler M, Wacker R. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. Trends Biotechnol 2005; 23: 208-216.
144. Penuelas I, Boan J, Marti-Climent JM, et al. Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. Mol Imaging Biol 2004; 6: 225-238.
145. Bogdanov A, Jr. In vivo imaging in the development of gene therapy vectors. Curr Opin Mol Ther 2003; 5: 594-602.
146. Min JJ, Gambhir SS. Gene therapy progress and prospects: norunvasive imaging of gene therapy in living subjects. Gene Ther 2004; 11: 115-125.
147. Segura J, Fillat C, Andreu D, et al. Monitoring Gene Therapy by External Imaging of mRNA: Pilot Study on Murine Erythropoietin. Ther Drug Monit 2007; 29: 612-618.
148. Roussel M, Mattei JP, Le Fur Y, et al. Metabolic determinants of the onset of acidosis in exercising human muscle: a 31P-MRS study. J Appl Physiol 2003; 94: 1145-1152.
149. WADA. Available: http://www.wada-ama.org/rtecontent/document/ Play_True_Turin.pdf. Accessed April 2007.